Zemplar
(Paricalcitol)ApprovedSmall molecule
AbbVieParicalcitol is used to treat low levels of parathyroid hormone and high phosphorus levels in people with chronic kidney disease. It helps regulate calcium and phosphorus balance in the body, especially in patients on dialysis.[2] Zemplar is currently approved and in use across 31 indications[4].[1]
Zemplar is one of 618 small molecule programs targeting Calcification. It is currently in Approved.
31
Indications
79
Total Trials
3
Active Trials
617
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 31 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zemplar
AbbVieApproved
Nolvadex
SSan Diego Pacific Oncology & Hematology Associates
Preclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Voltaren
NovartisPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Spravato
WWim Janssens
Preclinical
Chirocaine
PPurdue Pharma LP
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Kidney Disease13 trials
Show 10 more trials
Secondary Hyperparathyroidism12 trials
Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery
Completed·—·Phase 3·NCT01138475·49 enrolled
Show 9 more trials
Pancreatic Cancer9 trials
Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer
Terminated·—·Phase 1·NCT03520790·36 enrolled
Show 6 more trials
A Study of Neoadjuvant Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Completed·—·Phase 1·NCT02030860·15 enrolled
A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer
Terminated·—·Phase 1·NCT03519308·3 enrolled
Dialysis Patients3 trials
32 more indications
Anemia2 trials
Paricalcitol Improves Anemia of Inflammation
Terminated·—·Phase 4·NCT02876211·19 enrolled
Stage 5 Chronic Kidney Disease2 trials
Pancreatic Ductal Adenocarcinoma2 trials
Vitamin D2 trials
Effectiveness2 trials
Chronic Pancreatitis1 trial
A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis
Recruiting·—·Phase 1·NCT05664880·24 enrolled
Erythropoietin1 trial
Inflammation1 trial
Bone Disease1 trial
Nephropathy1 trial
Paricalcitol for the Treatment of Immunoglobulin A Nephropathy
Withdrawn·—·Phase 3·NCT00599963
Myelodysplastic Syndrome1 trial
Paricalcitol in Treating Patients With Myelodysplastic Syndrome
Completed·—·Phase 2·NCT00064376
Renal Transplant1 trial
Prostate Cancer1 trial
Alport syndrome1 trial
X-linked hypophosphatemic rickets1 trial
Multiple Myeloma1 trial
Diabetic Nephropathy1 trial
Radiation Therapy1 trial
End-Stage Renal Disease1 trial
Fasting Conditions1 trial
Bioequivalence Study of Paricalcitol Capsules, 4 mcg Under Fasting Conditions
Completed·—·Phase 1·NCT02322632·69 enrolled
Unspecified4 trials
Regulatory
FDA Approval Timeline[5]
Feb 1, 2000
ZEMPLAR
NDA NDA020819
May 26, 2005
ZEMPLAR
NDA NDA021606
Oct 21, 2014
PARICALCITOL
NDA NDA201657
Nov 18, 2014
PARICALCITOL
NDA NDA205917
Feb 4, 2016
PARICALCITOL
NDA NDA207174
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Zemplar drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Paricalcitol. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]